secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2026-08-04T10:01:26+00:00
Accession:  0001140361-26-031028
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics cuts 72% of workforce, sues Kuva Labs over merger breach
----------------------------------------------------------------------------

- Workforce reduced by ~72% effective immediately; estimated $1.2M in severance costs through Q3 2026.
- CMO Dr. Kristen K. Buck terminated without cause; entitled to 12 months salary and bonus plus COBRA.
- Company sued Kuva Labs in Delaware Chancery for breach of March 2026 merger agreement, seeking damages.
- Retention bonus of $200k approved for SVP James Nisco, contingent on employment through Dec 31, 2026.
- Company plans to pursue strategic options to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/0001140361-26-031028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/ef20079399_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-031028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer